First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.

ABSTRACT:

Purpose

¹²⁴I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under cellular stress and is a clinically validated oncotherapeutic target. We conducted a first-in-human study of microdose ¹²⁴I-PU-H71 for PET to study in vivo biodistribution, pharmacokinetics, metabolism, and safety; and the feasibility of epichaperome-targeted tumor imaging.

Experimental design

Adult patients with cancer (n = 30) received ¹²⁴I-PU-H71 tracer (201±12 MBq, <25 μg) intravenous bolus followed by PET/CT scans and blood radioassays.

Results

¹²⁴I-PU-H71 PET detected tumors of different cancer types (breast, lymphoma, neuroblastoma, genit

SUBMITTER: Dunphy MPS 

PROVIDER: S-EPMC7541604 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature